D1 Capital Partners has led a $102m series D round for Inflammatix, whose existing shareholders include Stanford-StartX Fund.

The spinout’s technology was fundamental to Oxford’s covid vaccine, prompting OSI and Future Planet Capital to back a $168m round.

The GMO, Mitsui Sumitomo and Samsung-backed furniture rental platform developer has added $1.4m to its latest round to take its total funding to $35m.

IBM Ventures participated in a $20m round for the neurological disease diagnostics technology spinout of Tel Aviv University.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Miyako Capital has contributed to a series A round for the cancer vaccine developer, which expanded to Japan last year.

The money will fund the progress of the University of London-linked precision medicine developer's lead drug candidate into the clinic.

Google subsidiary Gradient Ventures returned for a $14m second tranche of the round, having led the August 2020 first close.

Konishiyasu and Sojitz contributed to a series A round for the cancer vaccine developer, which expanded to their home of Japan last year.

SoftBank Vision Fund 2, Itochu and an unnamed insurer took part in a series C round that hiked the gene and cell therapy developer's total funding to $845m.